NCT02906332: A trial that was reported late by Hackensack Meridian Health
This trial has reported, although it was 22 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02906332 |
|---|---|
| Title | A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 12, 2016 |
| Completion date | May 31, 2022 |
| Required reporting date | May 31, 2023, midnight |
| Actual reporting date | June 22, 2023 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 22 |